Banisteriopsis caapi

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: mood anxiety detox

Research Overview

Research on Banisteriopsis caapi has most commonly been conducted in the context of ayahuasca, where B. caapi provides β-carboline alkaloids (notably harmine, harmaline, and tetrahydroharmine) that inhibit monoamine oxidase and thereby enable oral activity of co-administered DMT from Psychotria viridis. The most studied areas include ethnopharmacology and patterns of use (indigenous ritual/medical use and contemporary religious, therapeutic, and recreational contexts), pharmacology and mechanisms (MAO inhibition; downstream neuroendocrine, autonomic, and immune effects), safety/tolerability profiles, and early-stage therapeutic hypotheses for psychiatric disorders and addiction. A smaller but growing body of work examines neurobiological effects of B. caapi alkaloids independent of DMT, including cellular models of neurogenesis and neuroprotection relevant to mood disorders and neurodegenerative disease.

The strongest evidence supports well-characterized chemical and mechanistic roles for B. caapi β-carbolines within ayahuasca preparations, and measurable acute physiological effects in humans under controlled conditions. In a small double-blind randomized crossover study in healthy volunteers, encapsulated ayahuasca produced quantifiable DMT exposure and distinct subjective/neurophysiological effects, alongside autonomic and neuroendocrine changes (e.g., increased prolactin and cortisol) and transient immunomodulatory shifts in lymphocyte subpopulations. Preclinical evidence also supports biologically plausible neuroplasticity-related actions of B. caapi alkaloids: harmine, harmaline, tetrahydroharmine, and harmol stimulated proliferation, migration, and neuronal differentiation of adult neural progenitors in vitro, consistent with hypotheses linking these compounds to antidepressant-like effects. In vitro Parkinson’s disease models further suggest neuroprotective potential for ayahuasca and especially certain plant fractions, with metabolomics indicating that multi-compound mixtures (rather than isolated DMT alone) may better correlate with protective profiles.

Key gaps remain before firm clinical conclusions can be drawn. Human evidence is limited by small samples, heterogeneous preparations, and the difficulty of disentangling effects attributable specifically to B. caapi alkaloids versus DMT and contextual factors (“set and setting”), particularly in addiction-treatment reports that are largely qualitative and hypothesis-generating. More research is needed in the form of adequately powered, well-controlled clinical trials that standardize and chemically characterize B. caapi-containing preparations; establish dose–response relationships; and evaluate longer-term outcomes, safety (including drug–drug interactions relevant to MAO inhibition), and comparative efficacy versus existing treatments. Mechanistically, translational work is needed to connect in vitro neurogenesis/neuroprotection findings to in vivo biomarkers and clinically meaningful endpoints, and to clarify which constituents or combinations (e.g., specific β-carbolines and other co-occurring metabolites) drive observed effects.

1. What conditions has Banisteriopsis caapi been studied for?

  • Depression / antidepressant effects: Animal studies and “recent clinical research” are referenced as suggesting antidepressant activity of B. caapi preparations, with mechanistic work focusing on its β-carbolines (harmine, tetrahydroharmine, harmaline) and neurogenesis.

  • Addiction / substance use disorders: A qualitative empirical study examined ayahuasca-assisted therapy (ayahuasca includes B. caapi) in addiction treatment settings, generating hypotheses about mechanisms and outcomes.

  • Parkinson’s disease (PD) / neurodegeneration: An in vitro PD model (6-OHDA injury in SH-SY5Y cells) tested ayahuasca, extracts/fractions from B. caapi and P. viridis, and isolated alkaloids (including harmine) for neuroprotection.

  • Neuroprotection and cognition/memory: A systematic review of preclinical studies on harmine (a major B. caapi alkaloid) evaluated hippocampal neuron outcomes and memory-related behavioral tasks in animals.

  • Physiological/endocrine/immune effects in humans: A double-blind randomized crossover trial tested encapsulated freeze-dried ayahuasca (containing B. caapi β-carbolines plus DMT from P. viridis) for autonomic, neuroendocrine, and immunomodulatory effects.

  • Acute toxicity/safety: A rat study evaluated high-dose ayahuasca for lethality thresholds, behavioral effects, neuronal activation, and evidence of brain injury.

2. Does it work in treating those conditions? Summarize the evidence.

  • Depression

    • Mechanistic in vitro evidence (supports plausibility, not clinical efficacy): Harmine, tetrahydroharmine, harmaline, and harmol stimulated adult neurogenesis in vitro (proliferation, migration, differentiation) in neurospheres from adult mouse brain niches. Authors suggest brain plasticity/neurogenesis could contribute to antidepressant effects.

    • Animal behavioral/toxicity study (suggestive): In female Wistar rats, very high doses of ayahuasca produced behavioral changes interpreted as antidepressant-like (e.g., increased swimming vs controls in forced swim test), alongside strong neuronal activation in serotonergic-related regions; some brain injury was observed but “no permanent damage” detected. This is not direct evidence for B. caapi alone and used doses far above typical ritual exposure.

    • Clinical evidence: One abstract is a broad review stating “present day studies suggest” potential usefulness for psychiatric disorders/addictions, but it does not provide specific controlled trial outcomes for depression in the text provided.

  • Addiction

    • Qualitative evidence only: Interviews with therapists and treated individuals concluded ayahuasca “can serve as a valuable therapeutic tool” in structured settings and proposed mechanisms supporting recovery/relapse prevention. This is hypothesis-generating and not proof of efficacy (no randomized outcomes reported in the abstract).

  • Parkinson’s disease / neuroprotection

    • In vitro evidence (preclinical): In a 6-OHDA cell model, ayahuasca and plant extracts/fractions (including from B. caapi) were not cytotoxic and some samples increased viability; crude extracts/alkaloid fractions and harmine showed “remarkable neuroprotective effect” at 72h, while hydroalcoholic fractions showed neuroprotection at both 48h and 72h. Authors conclude potential applicability for PD, but this remains cell-culture evidence.

    • Isolated alkaloids vs mixtures: The hydroalcoholic fractions outperformed isolated alkaloids in that study, supporting (within that model) that mixtures/fractions may be more active than single compounds.

  • Cognition/memory (harmine)

    • Animal evidence: The harmine systematic review found harmine associated with neuroprotective effects (reduced excitotoxicity/inflammation/oxidative stress; increased BDNF) and improved learning/memory in several animal models. No human trials are described in the abstract.

Bottom line: The abstracts provided contain mostly preclinical (cell/animal) and qualitative evidence. They support biological plausibility and potential signals (depression-like behavior in animals; neuroprotection in vitro; cognitive effects in animals), but do not establish clinical efficacy of Banisteriopsis caapi as a stand-alone treatment for any condition.

3. What health benefits does it have?

  • Potential antidepressant-related mechanisms: B. caapi β-carbolines (harmine, tetrahydroharmine, harmaline; plus harmol) stimulated adult neurogenesis in vitro, which the authors link to antidepressant potential via brain plasticity.

  • Neuroprotective potential: In an in vitro PD model, B. caapi extracts/fractions and harmine showed neuroprotection against 6-OHDA toxicity and improved cell viability at certain time points/doses.

  • Possible cognitive/hippocampal benefits (preclinical): The harmine review reports reduced oxidative stress/inflammation and increased BDNF in preclinical studies, alongside improved memory/learning in animals.

  • Pharmacological role as an MAOI component in ayahuasca: The review abstracts emphasize that B. caapi β-carbolines inhibit monoamine oxidase (MAOI activity), enabling oral activity of DMT in traditional ayahuasca preparations (this is a pharmacologic effect, not necessarily a “health benefit”).

Important limitation: Most “benefits” described are mechanistic or preclinical; the abstracts do not provide strong controlled human evidence that B. caapi alone improves clinical outcomes.

4. Does it have any downsides or side effects?

  • Acute physiological effects in humans (ayahuasca trial; includes B. caapi + DMT)

    • Moderate sympathomimetic effects: Increased pupillary diameter (milder than amphetamine in that study).

    • Neuroendocrine stimulation: Prolactin increased significantly with ayahuasca; cortisol increased with both ayahuasca and amphetamine, with ayahuasca producing higher peak cortisol.

    • Immune cell shifts: Time-dependent changes in lymphocyte subpopulations (CD4 and CD3 decreased; natural killer cells increased), peaking around ~2 hours and returning to baseline by 24 hours. Authors recommend immunological assessment in long-term users.

  • Commonly reported undesired effects (from background summary)

    • Nausea and vomiting.

    • Hypertension and tachycardia.

  • High-dose animal toxicity findings (ayahuasca; includes B. caapi)

    • Lethality not reached: Lethal oral dose was >50× a ritual dose in female Wistar rats (50× corresponded to 15.1 mg/kg DMT in that preparation).

    • Behavioral suppression: Decreased locomotion in open field and elevated plus maze at high doses.

    • Neuronal activation and some injury: Increased c-fos activation in serotonergic-related regions; “some brain injury” observed, but “no permanent damage” detected in that study.

  • MAOI-related risk (mechanism-based concern): Because B. caapi is rich in MAOI β-carbolines, there is a plausible risk of drug/food interactions typical of MAO inhibition (the abstracts note MAOI activity but do not detail interaction cases).

Key limitation: Several adverse effects described come from studies of whole ayahuasca (which includes DMT) rather than isolated B. caapi; attribution specifically to B. caapi vs the combination is uncertain based on these abstracts alone.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic analyses (e.g., outcomes stratified by genetic variants) for Banisteriopsis caapi, harmine, or ayahuasca.

  • No direct evidence in these abstracts: There are no data on how genetic variation in drug-metabolizing enzymes or targets (e.g., MAO-A/MAO-B, CYP enzymes, serotonin receptors/transporters) changes efficacy or risk.

  • Mechanism-based implication (not proven here): Because B. caapi contains MAOI β-carbolines and ayahuasca produces measurable endocrine/immune changes, it is plausible that genetic differences affecting monoamine metabolism or signaling could influence response or adverse effects, but this remains speculative without genotype-stratified studies.

References

  1. Ayahuasca: Pharmacology, neuroscience and therapeutic potential.
    Elisabet Domínguez-Clavé, Joaquim Soler, Matilde Elices, Juan C Pascual, Enrique Álvarez, Mario de la Fuente Revenga, Pablo Friedlander, Amanda Feilding, Jordi Riba (2016) - Brain research bulletin
  2. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.
    Jonathan Hamill, Jaime Hallak, Serdar M Dursun, Glen Baker (2019) - Current neuropharmacology
  3. Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids
    Andreia Machado Brito-da-Costa, Diana Dias-da-Silva, Nelson G M Gomes, Ricardo Jorge Dinis-Oliveira, Áurea Madureira-Carvalho (2020) - Pharmaceuticals (Basel, Switzerland)
  4. The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro.
    Jose A Morales-García, Mario de la Fuente Revenga, Sandra Alonso-Gil, María Isabel Rodríguez-Franco, Amanda Feilding, Ana Perez-Castillo, Jordi Riba (2017) - Scientific reports
  5. Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence--qualitative results.
    Anja Loizaga-Velder, Rolf Verres (2014) - Journal of psychoactive drugs
  6. Neuroprotective potential of Ayahuasca and untargeted metabolomics analyses: applicability to Parkinson's disease.
    Albert Katchborian-Neto, Wanderleya T Santos, Karen J Nicácio, José O A Corrêa, Michael Murgu, Thaís M M Martins, Dawidson A Gomes, Alfredo M Goes, Marisi G Soares, Danielle F Dias, Daniela A Chagas-Paula, Ana C C Paula (2020) - Journal of ethnopharmacology
  7. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.
    Rafael G Dos Santos, Marta Valle, José Carlos Bouso, Josep F Nomdedéu, José Rodríguez-Espinosa, Ethan H McIlhenny, Steven A Barker, Manel J Barbanoj, Jordi Riba (2011) - Journal of clinical psychopharmacology
  8. Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotria viridis) in female Wistar rat.
    Aline Pic-Taylor, Luciana Gueiros da Motta, Juliana Alves de Morais, Willian Melo Junior, Alana de Fátima Andrade Santos, Leandro Ambrósio Campos, Marcia Renata Mortari, Marcus Vinicius von Zuben, Eloisa Dutra Caldas (2015) - Behavioural processes
  9. Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use.
    Daniel Perkins, Simon G D Ruffell, Kimberley Day, Diego Pinzon Rubiano, Jerome Sarris (2022) - Frontiers in neuroscience
  10. Ayahuasca: A review of historical, pharmacological, and therapeutic aspects.
    Simon G D Ruffell, Max Crosland-Wood, Rob Palmer, Nige Netzband, WaiFung Tsang, Brandon Weiss, Sam Gandy, Tessa Cowley-Court, Andreas Halman, Diana McHerron, Angelina Jong, Tom Kennedy, Eleanor White, Daniel Perkins, Devin B Terhune, Jerome Sarris (2023) - PCN reports : psychiatry and clinical neurosciences
  11. Effects of the Natural β-Carboline Alkaloid Harmine, a Main Constituent of Ayahuasca, in Memory and in the Hippocampus: A Systematic Literature Review of Preclinical Studies.
    Rafael G Dos Santos, Jaime E C Hallak (2017) - Journal of psychoactive drugs
  12. Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015.
    C William Heise, Daniel E Brooks (2017) - Journal of medical toxicology : official journal of the American College of Medical Toxicology
  13. Ayahuasca and Its DMT- and β-carbolines - Containing Ingredients Block the Expression of Ethanol-Induced Conditioned Place Preference in Mice: Role of the Treatment Environment.
    Elisangela G Cata-Preta, Yasmim A Serra, Eliseu da C Moreira-Junior, Henrique S Reis, Natali D Kisaki, Matheus Libarino-Santos, Raiany R R Silva, Thaísa Barros-Santos, Lucas C Santos, Paulo C R Barbosa, José L Costa, Alexandre J Oliveira-Lima, Lais F Berro, Eduardo A V Marinho (2018) - Frontiers in pharmacology
  14. Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant.
    Giordano Novak Rossi, Lorena T L Guerra, Glen B Baker, Serdar M Dursun, José Carlos Bouso Saiz, Jaime E C Hallak, Rafael G Dos Santos (2022) - Biomolecules
  15. Ayahuasca blocks ethanol preference in an animal model of dependence and shows no acute toxicity.
    Bruno Gianfratti, Ricardo Tabach, Marna Eliana Sakalem, Talita Stessuk, Lucas Oliveira Maia, Elisaldo Araujo Carlini (2022) - Journal of ethnopharmacology
  16. Exposure to ayahuasca induces developmental and behavioral alterations on early life stages of zebrafish.
    Thayres S Andrade, Rhaul de Oliveira, Muriel Lopes da Silva, Marcus Vinicius Von Zuben, Cesar Koppe Grisolia, Inês Domingues, Eloisa Dutra Caldas, Aline Pic-Taylor (2018) - Chemico-biological interactions
  17. Evaluation of the Cytotoxicity of Ayahuasca Beverages.
    Ana Y Simão, Joana Gonçalves, Ana Gradillas, Antonia García, José Restolho, Nicolás Fernández, Jesus M Rodilla, Mário Barroso, Ana Paula Duarte, Ana C Cristóvão, Eugenia Gallardo (2020) - Molecules (Basel, Switzerland)
  18. Ayahuasca: pharmacology, safety, and therapeutic effects.
    Rafael Guimarães Dos Santos, Jaime Eduardo Cecilio Hallak (2024) - CNS spectrums
  19. Components ofBanisteriopsis caapi, a Plant Used in the Preparation of the Psychoactive Ayahuasca, Induce Anti-Inflammatory Effects in Microglial Cells
    Beatriz Werneck Lopes Santos, Daniel Carneiro Moreira, Tatiana Karla Dos Santos Borges, Eloisa Dutra Caldas (2022)
  20. Ayahuasca as a Decoction Applied to Human: Analytical Methods, Pharmacology and Potential Toxic Effects.
    Ľuboš Nižnanský, Žofia Nižnanská, Roman Kuruc, Andrea Szórádová, Ján Šikuta, Anežka Zummerová (2022) - Journal of clinical medicine


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!